Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metabolism
100%
Hepatocellular Carcinoma Cells
100%
Sorafenib Resistance
100%
Orlistat
100%
Combination Treatment
80%
Huh7
80%
Fatty Acid Synthase
60%
Fatty Acid Synthesis
60%
Flow Cytometry
40%
Glucose Uptake
40%
Western Blot
40%
Sorafenib
40%
18F-fluorodeoxyglucose (18F-FDG)
40%
FDG Uptake
40%
Cytotoxicity
20%
Decreased Expression
20%
Protein Expression
20%
Possible Mechanisms
20%
Hepatocellular Carcinoma
20%
Cell Killing
20%
Flow Alteration
20%
High Glucose
20%
Bcl-2 Expression
20%
Cell Cycle Distribution
20%
Huh7 Cells
20%
Strategies to Overcome
20%
Glucose Metabolism
20%
Cell Metabolism
20%
Advanced Hepatocellular Carcinoma
20%
Median Overall Survival
20%
Sorafenib-resistant
20%
Sorafenib-resistant Hepatocellular Carcinoma
20%
Fatty Acid Synthase Inhibitor
20%
Hepatocellular Carcinoma Treatment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Sorafenib
100%
Tetrahydrolipstatin
100%
Fatty Acid Synthase
33%
Fatty Acid
33%
Western Blot
22%
Flow Cytometry
22%
Overall Survival
11%
Fatty Acid Synthase Inhibitor
11%
Cytotoxicity
11%
Immunology and Microbiology
Carcinoma Cell
100%
Sorafenib
100%
Cell Line
33%
Fatty Acid Synthesis
33%
Glucose Transport
22%
Western Blot
22%
Cytotoxicity
11%
Protein Expression
11%
Cell Cycle
11%
Bcl-2
11%
Overall Survival
11%
Cell Killing
11%
Cell Metabolism
11%
Glucose Metabolism
11%